MedTrace Logo

Effectiveness of "Medisinstart"

NCT02261402 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1480

Last updated 2021-07-20

No results posted yet for this study

Summary

"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.

The main purpose of this study is to investigate whether "Medisinstart" increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if "Medisinstart" has additional benefits for the patient, the society and the pharmacies.

Conditions

Interventions

OTHER

Medisinstart

"Medisinstart" is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.

Sponsors & Collaborators

  • Norwegian Pharmacy Association

    collaborator OTHER

  • Apokus AS

    lead OTHER

Principal Investigators

  • Karine W Ruud, PhD · Apokus AS

  • Sara Bremer, PhD · Apokus AS

  • Ragnar Hovland, PhD · Photocure ASA (current affiliation), Apokus AS (until Dec. 2016)

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-12-31
Completion
2017-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02261402 on ClinicalTrials.gov